[Press release] ACTG launches IPACE-HIV to study frailty intervention

ACTG press release

CHAPEL HILL, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study (Improving Physical Ability and Cellular Senescence Elimination in HIV), also known as A5426. IPACE-HIV is a phase 2, double-blind, randomized study evaluating the safety, tolerability, and efficacy of dasatinib and quercetin in improving physical function outcomes in people living with HIV who are frail or exhibit symptoms that they may become frail.

People living with HIV often experience diseases and conditions, including frailty, that are associated with aging at younger ages than people who are not living with HIV. This is true even among individuals whose HIV is well-controlled on antiretroviral treatment. Current treatment for physical function impairment and frailty in people living with HIV focuses on non-pharmacologic interventions such as exercise, nutritional support, and management of the comorbidities that can contribute to frailty. Dasatinib and quercetin are senolytics, drugs targeting the cells that play a role in biologic aging. Clinical trials involving this regimen have shown promise in reversing some of the symptoms and signs of frailty, but to date these studies have not included people living with HIV.

Read the full press release here.